Revamp coming at Gilead; Latest from in Ukraine, Russia; Biogen’s hanging budget ax; Novartis places gene therapy bet; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Amid a big Omicron outbreak here in Hong Kong, I recently caught Covid-19 but thankfully only had mild symptoms and have already recovered. Still, the experience gave me even more appreciation of rapid antigen tests and vaccines — and the people in this industry behind those very real medical products shaping our lives. Have a good weekend.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.